Drug Patents owned by Bayer Healthcare

1. List of Aliqopa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511041 BAYER HEALTHCARE Fused azole-pyrimidine derivatives
May, 2024

(1 year, 3 months from now)

USRE46856 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Oct, 2029

(6 years from now)

US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 14, 2022
Orphan Drug Exclusivity (ODE) Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ALIQOPA family patents

7

European Union

5

United States

3

Spain

3

Cyprus

3

Japan

3

Slovenia

3

Argentina

3

Portugal

3

Croatia

3

Taiwan, Province of China

3

Denmark

3

Ecuador

2

Austria

2

Hong Kong

2

Morocco

2

Korea, Republic of

2

Brazil

2

Australia

2

Poland

2

Malaysia

2

Ukraine

2

Uruguay

2

Israel

2

Mexico

2

South Africa

2

Peru

2

China

2

New Zealand

2

Canada

1

RS

1

AP

1

Chile

1

Cuba

1

Guatemala

1

Dominican Republic

1

Jordan

1

Germany

1

Tunisia

1

Colombia

1

Russia

1

Singapore

1

ME

1

EA

1

Norway

1

San Marino

1

Costa Rica

2. List of Nubeqa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9657003 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US10711013 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US11046713 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US10383853 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(12 years from now)

US10010530 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(12 years from now)

US11168058 BAYER HEALTHCARE Manufacture of a crystalline pharmaceutical product
Feb, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515 BAYER HEALTHCARE Carboxamide derivative and its diastereomers in stable crystalline form
Jan, 2036

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 30, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

NUBEQA family patents

16

United States

14

European Union

5

Finland

5

Poland

5

Spain

5

Japan

5

Slovenia

5

Hungary

5

Portugal

5

Denmark

4

RS

4

Korea, Republic of

4

Brazil

4

Lithuania

4

China

4

Croatia

3

Australia

3

Ukraine

3

Israel

3

Canada

2

Hong Kong

2

Chile

2

Cyprus

2

Mexico

2

South Africa

2

EA

1

Malaysia

1

Luxembourg

1

Netherlands

1

Argentina

1

Colombia

1

Georgia

1

Peru

1

Russia

1

Norway

1

San Marino

1

New Zealand

3. List of Vitrakvi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9127013 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US8513263 BAYER HEALTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(6 years from now)

US10172861 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US10799505 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9676783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(6 years from now)

US10774085 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(6 years from now)

US9447104 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(6 years from now)

US8865698 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(6 years from now)

US10005783 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US10047097 BAYER HEALTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(6 years from now)

US9782414 BAYER HEALTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(12 years from now)

US10045991 BAYER HEALTHCARE Methods of treating pediatric cancers
Apr, 2037

(14 years from now)

US10668072 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(14 years from now)

US10137127 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Apr, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 26, 2025
New Chemical Entity Exclusivity (NCE) Nov 26, 2023

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating cancerous solid tumors; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating solid tumors that exhibit an ntrk fusion gene in a pediatric patient; Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution

Dosage: SOLUTION;ORAL

More Information on Dosage

VITRAKVI family patents

37

United States

9

Korea, Republic of

9

Japan

8

European Union

7

Taiwan, Province of China

6

Australia

6

Chile

6

Israel

6

Russia

6

Singapore

6

China

4

Brazil

4

Poland

4

Lithuania

4

Ukraine

4

Spain

4

Mexico

4

Slovenia

4

Hungary

4

Portugal

4

Philippines

4

Canada

4

Denmark

3

Hong Kong

3

Morocco

3

RS

3

Cyprus

3

Tunisia

3

Argentina

3

Colombia

3

Croatia

3

Costa Rica

2

Norway

1

Cuba

1

Malaysia

1

Luxembourg

1

Dominican Republic

1

Uruguay

1

Netherlands

1

Ecuador

1

South Africa

1

Georgia

1

Peru

1

ME

1

Turkey

1

San Marino

1

New Zealand

1

Nicaragua

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in